دورية أكاديمية
Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study.
| العنوان: | Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study. |
|---|---|
| المؤلفون: | Schjesvold FH; Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway.; KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway., Ludwig H; Medical Department Center for Oncology, Hematology and Palliative Medicine, Wilhelminen Cancer Research Institute, Vienna, Austria., Mateos MV; Institute of Cancer Molecular and Cellular Biology, University Hospital of Salamanca, Salamanca, Spain., Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, Italy., Abdulhaq H; Department of Hematology and Oncology, University of California, San Francisco, Fresno, California, USA., Norin S; Clinical Science, Oncopeptides AB, Stockholm, Sweden., Thuresson M; Biostatistics, Oncopeptides AB, Stockholm, Sweden., Bakker NA; Clinical Science, Oncopeptides AB, Stockholm, Sweden., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. |
| المصدر: | European journal of haematology [Eur J Haematol] 2024 Mar; Vol. 112 (3), pp. 402-411. Date of Electronic Publication: 2023 Nov 15. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2005->: Oxford : Blackwell Original Publication: Copenhagen : Munksgaard, c1987- |
| مواضيع طبية MeSH: | Multiple Myeloma*/diagnosis , Multiple Myeloma*/drug therapy , Hematopoietic Stem Cell Transplantation*, Melphalan/*analogs & derivatives , Phenylalanine/*analogs & derivatives , Thalidomide/*analogs & derivatives, Humans ; Melphalan/therapeutic use ; Alkylating Agents/therapeutic use ; Dexamethasone/adverse effects ; Transplantation, Autologous ; Antineoplastic Combined Chemotherapy Protocols/adverse effects |
| مستخلص: | Melphalan flufenamide (melflufen), a first-in-class alkylating peptide-drug conjugate, plus dexamethasone demonstrated superior progression-free survival (PFS), but not overall survival (OS), versus pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma in the OCEAN study. Time to progression (TTP) <36 months after a prior autologous stem cell transplantation (ASCT) was a negative prognostic factor for OS with melflufen. This post hoc exploratory analysis evaluated patients refractory to prior alkylators (e.g., cyclophosphamide and melphalan) in OCEAN. In 153 patients refractory to prior alkylators (melflufen, n = 78; pomalidomide, n = 75), the melflufen and pomalidomide arms had similar median PFS (5.6 months [95% CI, 4.2-8.3] vs. 4.7 months [95% CI, 3.1-7.3]; hazard ratio [HR], 0.92 [95% CI, 0.63-1.33]) and OS (23.4 months [95% CI, 14.4-31.7] vs. 20.0 months [95% CI, 12.0-28.7]; HR, 0.92 [95% CI, 0.62-1.38]). Among alkylator-refractory patients with a TTP ≥ 36 months after a prior ASCT or no prior ASCT (melflufen, n = 54; pomalidomide, n = 53), the observed median PFS and OS were longer in the melflufen arm than the pomalidomide arm. The safety profile of melflufen was consistent with previous reports. These results suggest that melflufen is safe and effective in patients with alkylator-refractory disease, suggesting differentiated activity from other alkylators. (© 2023 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.) |
| References: | Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122-1128. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9. Chauhan D, Ray A, Viktorsson K, et al. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013;19(11):3019-3031. Gullbo J, Tullberg M, Våbenø J, et al. Structure-activity relationship for alkylating dipeptide nitrogen mustard derivatives. Oncol Res. 2003;14(3):113-132. Gullbo J, Wickstrom M, Tullberg M, et al. Activity of hydrolytic enzymes in tumour cells is a determinant for anti-tumour efficacy of the melphalan containing prodrug J1. J Drug Target. 2003;11(6):355-363. Ray A, Ravillah D, Das DS, et al. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016;174(3):397-409. Wickstrom M, Viktorsson K, Lundholm L, et al. The alkylating prodrug J1 can be activated by aminopeptidase N, leading to a possible target directed release of melphalan. Biochem Pharmacol. 2010;79(9):1281-1290. Wickström M, Nygren P, Larsson R, et al. Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017;8(39):66641-66655. Pepaxti: Summary of Product Characteristics - European Medicines Agency. 2022 Accessed June 14, 2023. https://www.ema.europa.eu/en/documents/product-information/pepaxti-epar-production-information_en.pdf. Richardson PG, Oriol A, Larocca A, et al. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma. J Clin Oncol. 2021;39(7):757-767. Schjesvold FH, Dimopoulos MA, Delimpasi S, et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022;9(2):e98-e110. Sonneveld P, Richardson PG, Ludwig H, et al. Benefit versus risk assessment of melflufen and dexamethasone in relapsed/refractory multiple myeloma: analyses from longer follow-up of the OCEAN and HORIZON studies. Clin Lymphoma Myeloma Leuk. 2023;23(9):687-696. Rodríguez-Otero P, Mateos M-V, Oriol A, et al. Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: a pooled analysis of the O-12-M1 and HORIZON studies. J Clin Oncol. 2021;39:8048. Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105-e118. Jagannath S, Vesole DH, Glenn L, Crowley J, Barlogie B. Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood. 1992;80(7):1666-1672. Gertz MA, Lacy MQ, Inwards DJ, et al. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma. Bone Marrow Transplant. 1997;20(5):375-380. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986;67(5):1298-1301. Selby PJ, McElwain TJ, Nandi AC, et al. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol. 1987;66(1):55-62. Richardson PG, Bringhen S, Voorhees P, et al. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020;7(5):e395-e407. Goldsmith SR, Fiala MA, Wang B, et al. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma. Ann Hematol. 2020;99(5):1041-1048. Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8(11):109. |
| معلومات مُعتمدة: | Oncopeptides AB |
| فهرسة مساهمة: | Keywords: alkylating agent; melflufen; melphalan flufenamide; multiple myeloma; pomalidomide; stem cell transplantation |
| المشرفين على المادة: | 3412470A0V (melflufen) Q41OR9510P (Melphalan) D2UX06XLB5 (pomalidomide) 0 (Alkylating Agents) 7S5I7G3JQL (Dexamethasone) 47E5O17Y3R (Phenylalanine) 4Z8R6ORS6L (Thalidomide) |
| تواريخ الأحداث: | Date Created: 20231116 Date Completed: 20240219 Latest Revision: 20240219 |
| رمز التحديث: | 20240219 |
| DOI: | 10.1111/ejh.14127 |
| PMID: | 37968873 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1600-0609 |
|---|---|
| DOI: | 10.1111/ejh.14127 |